Drug Profile


Alternative Names: BPSC-1001; Ebola vaccine - Merck & Co; Ebola virus vaccine - NewLink Genetics; Public Health Agency of Canada's Ebola vaccine; rVSV delta G ZEBOV GP; rVSV-EBOV; rVSV-S-GP/VP40; rVSV-ZEBOV; rVSV-ZEBOV-GP; V-920; VSV delta G ZEBOV; VSV delta-ZEBOV; VSV-EBOV; VSV-ZEBOV; VSVG-ZEBOV

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Public Health Agency of Canada
  • Developer Canadian Immunization Research Network; Centers for Disease Control and Prevention; Merck & Co; National Institute of Allergy and Infectious Diseases; NewLink Genetics Corporation; Norwegian Institute of Public Health; University of Oxford; VEBCON Consortium
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for rVSV S GP/VP40 in USA (Merck Annual report 2016)
  • 26 Oct 2016 Adverse events data from the phase II/III STRIVE trial in Ebola virus infections presented at the ID Week 2016
  • 18 Oct 2016 Canadian Immunization Research Network plans a clinical trial for Ebola virus infections (Prevention, in HIV positive patients) in Canada, Senegal and Burkina Faso
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top